A.A. ROMANOVA, D.V. PECHKUROV, A.A. TYAZHEVA, G.V. YUSHINA

 Samara State Medical University, Samara

Contact details:

Pechkurov D.V. — MD, Professor, Head of the Department of Children’s Diseases

Address: 89 Chapayevskaya St., Samara, Russian Federation, 443099, tel.: +7 (846) 959-45-11, e-mail: dmpechkurov@ yandex.ru

Numerous studies and clinical observations demonstrate the role of the new coronavirus infection in the formation of various organs and systems pathologies. The article presents a clinical case of the development of post-infectious colitis in a girl who suffered COVID-19. Gastrointestinal symptoms appeared as early as in the acute period of the disease and, despite the symptomatic treatment, progressed within 6 months. During the examination, there was a sharp increase in the level of fecal calprotectin, a moderate increase in the level of CRP, stool with mucus and streaks of blood, the girl lost several kilograms in six months. According to endoscopic and morphological examination, superficial inflammation was noted without signs characteristic of ulcerative colitis and Crohn’s disease. Against the background of taking mesalazine, the condition somewhat improved, but after 2 months it worsened again; during repeated examination, a high level of calprotectin remained with negative serological markers and no endoscopic signs of inflammatory bowel disease. Obviously the girl has postinfectious colitis; further observation will allow establishing its nature and the disease prognosis.

Key words: children, COVID-19, postinfectious colitis, treatment.

REFERENCES

1. Drapkina O.M., Samorodskaya I.V., Sivtseva M.G. et al. COVID-19: urgent issues of assessing morbidity, prevalence, mortality and mortality. Profilakticheskaya meditsina, 2020, vol. 23, no. 1, pp. 7–13 (in Russ.). DOI: 10.17116/profmed2020230117
2. Fomina L.A., Nemirov K.E., Sakharova E.M. Gastroenterological manifestations of SARS-COV-2 and possible consequences of the infection. Eksperimental’naya i klinicheskaya gastroenterologiya, 2022, no. 4 (200), pp. 9–13 (in Russ.). DOI: 10.31146/1682-8658-ecg-200-4-9-13
3. Murkamilov I.T., Aytbaev K.A., Murkamilova Zh.A. et al. Coronavirus disease-2019 (COVID-19): course and long-term consequences. Byulleten’ nauki i praktiki, 2021, vol. 7, no. 9, pp. 271–291 (in Russ.).
4. Galeotti C., Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat. Rev. Rheumatol, 2020, vol. 16 (8), pp. 413–14. DOI: 10.1038/s41584-020-0448-7
5. Askanase A.D., Khalili L. 2020, vol. 7 (1), p. e000396. DOI: 10.1136/lupus-2020-000396
6. Canas C.A. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med. Hypotheses, 2020, vol. 145, p. 110345. DOI: 10.1016/j.mehy.2020.110345
7. Liu Y., Sawalha A.H., Lu Q. COVID-19 and autoimmune diseases. Curr. Opin. Rheumatol, 2020. DOI: 10.1097/BOR.0000000000000776
8. Xie Y., Liu Y., Liu Y. The Flare of Rheumatic Disease After SARS-CoV-2 Vaccination: A Review. Front. Immunol, 2022, vol. 13, pp. 919–979. DOI: 10.3389/fimmu.2022.919979
9. Sakki M.K., Tamiatstso S., Stobbione P. SARS-CoV-2 infection as an autoimmune response trigger. Klinicheskiy perevod Sci, 2021, no. 14 (3), pp. 898–907 (in Russ.). DOI: 10.1111 / cts.12953
10. Wang Y., Perlman S. COVID-19: Inflammatory profile. Annu. Rev. Med, 2022, vol. 73, pp. 65–80.
11. Fajgenbaum D. C., June C.H. Cytokine storm. New Engl. J. Med, 2020, vol. 383, pp. 2255–2273.
12. Zhang F., Mears J.R., Shakib L.et al. IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Med, 2021, vol. 13, p. 64. DOI: 10.1186/s13073-021-00881-3
13. Kornienko E.A. Vospalitel’nye zabolevaniya kishechnika u detey [Inflammatory bowel disease in children]. Moscow: Prima Print, 2019. Pp. 18–27.